Joseph Thome

“Maybe just one, I guess still trying to understand a little bit in the recently completed juvenile NHP study that you've completed. I guess mechanistically why exposures would be lower in juvenile NHPs versus adults, if you can kind of help us with that.”

“Maybe just one, I guess still trying to understand a little bit in the recently completed juvenile NHP study that you've completed. I guess mechanistically why exposures would be lower in juvenile NHPs versus adults, if you can kind of help us with that.”

“Can you comment a little bit on your CMC readiness for the LOMBO-Z potential approval and launch and if there were any manufacturing changes between the Phase II and the Phase III?”

“Maybe to follow up on the Huntington's program, I guess, now that Novartis is in charge of the program, are they also in charge of any further disclosures from the Phase 1-2 program, or should we expect anything in May of this year, kind of how does that work?”

“Maybe on the PSC study now that that one is fully enrolled, are you able to talk a little bit about the baseline criteria of the patients that were enrolled, especially as it relates to the population that was studied in the interim analysis population.”